Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Worries that ...

Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with ...

The treatment of rheumatoid arthritis has changed over the last 15 ... have become the norm. TNF inhibitors were the first biologic agents available to rheumatologists and are still currently ...

Tumor necrosis factor (TNF) inhibitors led to no significant difference in survival or respiratory-related hospitalizations compared with non-TNF inhibitors, in patients with rheumatoid arthritis ...

The investigators were thus able to identify the cancer risk in a large national cohort of 6,366 patients with RA who first started treatment with TNF inhibitors between January 1999 and July 2006.

And the final risk that uh we know is associated with TNF inhibitors is the risk of lymphoma. Now, again, it's a very, very small risk and it's complicated because rheumatoid arthritis itself has ...

Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

Anakinra is an interleukin 1 receptor antagonist that is approved for the treatment of RA for use alone or in combination with DMARDs other than TNF inhibitors. Rituximab, a mAb that binds to CD20 ...

In recent years, there's been a revolution in Disease-Modifying Antirheumatic Drugs, known as DMARDs, available to control RA, driven largely by biologic therapies. What are these agents, exactly?

Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid arthritis (RA) are unfounded, at least for U.S. military veterans ...